Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer
In a study of plasma and tissue platelet derived growth factor (PDGF) concentration in patients with breast cancer, elevated levels of plasma PDGF were found in a significant proportion, 11/37 (30%), of patients. Sixteen patients (43%) had tumors which expressed PDGF-AA and 6 patients had tumors which in addition expressed the BB isoform of PDGF. All patients with elevated plasma levels of platelet derived growth factor had tumors which expressed the growth factor on immunohistochemical staining of tumor cells. Furthermore there was a significant correlation between plasma levels of platelet derived growth factor and the intensity of tissue staining. Patients with stage four breast cancer with tumors which were positive for platelet derived growth factor had a significantly lower response rate to chemotherapy as well as significantly shorter duration of survival. In addition, patients with stage four breast cancer who had elevated plasma PDGF levels had a significantly shorter survival. These results indicate that elevated plasma levels of platelet derived growth factor in patients with breast cancer are derived from the tumor cells and suggest that platelet derived growth factor may play a significant role in control tumor cell growth.
Key wordsplatelet derived growth factor breast cancer immunohistochemistry prognosis tumor progression
Unable to display preview. Download preview PDF.
- 1.Deinhardt F: Biology of primate retroviruses. In: Klein G (ed) Viral Oncology. Raven, New York, 1980Google Scholar
- 2.Perosio PM, Brooks JJ: Expression of growth factors and growth factor receptors in soft tissue tumors: implications for the autocrine hypothesis. Lab Invest 60: 245–253, 1989Google Scholar
- 3.Ito M, Yoshida K, Kyo E, Ayhan A, Nayakama H, Yasui W, Ito H, Tahara E: Expression of several growth factors and their receptor genes in human colon carcinomas. Virchows Arch 59: 173–178, 1990Google Scholar
- 4.Wang JL, Nister M, Hermansson M, Westermark B, Ponten J: Expression of PDGF β-receptors in human meningioma cells. Int J Cancer 46: 772–778, 1990Google Scholar
- 5.Leveen P, Claesson-Welsh L, Heldin CH, Westermark B, Betsholtz C: Expression of messenger RNA's for platelet derived growth factor and its receptors in human sarcoma cell lines. Int J Cancer 46: 1066–1070, 1990Google Scholar
- 6.Bronzert DA, Pantazis P, Antoniades HN, Kasid A, Davidson N, Dickson RB, Lippman ME: Synthesis and secretion of platelet derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci 84: 5763–5767, 1987Google Scholar
- 7.Ariad S, Seymour L, Bezwoda WR: Platelet derived growth factor (PDGF) in plasma of patients with breast cancer: correlation with stage and rate of progression. Breast Cancer Res Treat 20: 11–17, 1991Google Scholar
- 8.Heldin CH, Betsholtz C, Johnsson A, Westermark B: Role of PDGF-like growth factors in malignant transformation. Cancer Rev 2: 34–39, 1986Google Scholar
- 9.Pantazis P, Goustin AS, Nixon J: Platelet derived growth factor and its receptor in blood cell differentiation and neoplasia. Eur J Haematol 45: 127–138, 1990Google Scholar
- 10.Wakefield L, Thompson N, Flanders K, O'Connor-McCourt M, Sporn M: Transforming growth factor-beta: multifunctional regulator of cell growth and phenotype. Ann NY Acad Sci: 290-297, 1989Google Scholar
- 11.Lippman ME, Dickson RB, Gelmann EP, Rosen N, Knabbe C, Bates S, Bronzert D, Huff K, Kasid A: Growth regulation of human breast cancer occurs through regulated growth factor secretion. J Cell Biochem 35: 1–19, 1987Google Scholar
- 12.Mannucci PM, Cattaneo M, Canciani MT, Manniezzo M, Vaglini M, Cascinelli N: Early evidence of activated (exhausted) platelets in malignant tumors (breast adenocarcinoma and malignant melanoma). Eur J Cancer Clin Oncol 25: 1413–1417, 1989Google Scholar